Grifols Biopharma

We are very pleased that the U.S. FDA has approved an expanded label for XEMBIFY® to include treatment-naïve patients with primary humoral immunodeficiencies. It is the first and only 20% subcutaneous immunoglobulin (SCIg) that enables patients to go straight to SCIg without initial intravenous Ig therapy. The extended label, which also includes biweekly dosing, provides patients with added flexibility and convenience. Increasing adoption of XEMBIFY is part of Grifols’ broader Ig business strategy focused on treating immunodeficiencies, which represent more than half of the total Ig market. For more information, see the press release. 👉 http://spr.ly/6048cWzfj #Immunology #WeAreInnovation

Innovation in the field of transfusion medicine has been a fundamental pillar in the advancement of diagnostics. At Grifols, we have witnessed and played a leading role in this evolution. Our commitment to innovation has led us to develop technologies that have marked a before and after in medical diagnostics. From the creation of a lamp used for Rh determination in the 1950’s to the introduction of a processor that automated the gel agglutination technique in 1993, we have demonstrated an unwavering commitment to continuous improvement and innovation. Explore our history, share our legacy, and be part of the innovation that defines Grifols 👉 http://spr.ly/60485lhBp #Transfusionmedicine #diagnostics #Since1909

As part of GBS/CIDP Awareness Month, we continue to do our part in raising awareness of these rare neurological autoimmune disorders, characterized by inflammation and damage to nerve roots, and peripheral nerves. Chronic inflammatory demyelinating polyneuropathy, or CIDP, affects an estimated 450,000 individuals worldwide, with a higher prevalence in males aged 40-60. At Grifols, we strive to improve the health and well-being of people globally and are dedicated to researching innovative solutions for treating chronic and rare diseases like CIDP. Inspired by individuals like Nancy and Adriann, who face CIDP with resilience and optimism, we continue our mission to make a meaningful difference in patients’ lives. Their unwavering spirit serves as a reminder that despite the challenges, embracing life with positivity and determination is key. #cidpawarenessmonth #neurology #WhatWeDoMatters

Throughout May, as we observe GBS/CIDP Awareness Month, we stand alongside the patient community and our esteemed patient organization partners worldwide to shine a light on these rare neurological autoimmune disorders. GBS is an acute inflammatory disorder that causes muscle weakness and sometimes paralysis. CIPD on the other hand is a chronic neurological disease in which the immune system attacks and damages the protective coating covering the nerves, causing weakness, pain, numbness, and tingling in the arms and legs, as well as loss of balance that may impair the ability to walk. It’s estimated that 450,000 people worldwide are impacted by CIDP. 👍 Join us in spreading awareness of #GBS and #CIDP by liking this post and showing your support! #cidpawarenessmonth #neurology #WhatWeDoMatters